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Background: This retrospective study investigated the outcome of patients with brain metastases after radiosurgery
with special emphasis on prognostic impact of visible intratumoral necrosis on survival and local control.
Methods: From 1998 through 2008, 149 patients with brain metastases from solid tumors were treated with
stereotactic radiotherapy at Luebeck University. Median age was 58.4 years with 11%, 78%, 10% in recursive
partitioning analysis (RPA) classes I, II, III, respectively. 70% had 1 metastasis, 29% 2-3 metastases, 2 patients more
than 3 metastases, 71% active extracranial disease. Median volume of metastatic lesions was 4.7 cm3, median
radiosurgery dose 22 Gy (single fraction). 71% of patients received additional whole-brain irradiation (WBI). All
patients were analyzed regarding survival, local, distant failure and prognostic factors, side effects and changes in
neurologic symptoms after radiotherapy. The type of contrast-enhancement in MR imaging was also analyzed;
metastatic lesions were classified as containing necrosis if they appeared as ring-enhancing with central areas of no
or minimal contrast enhancement.
Results: Median survival was 7.0 months with 1-year and 5-year survival rates of 33% and 0.4%, respectively. Tumor
necrosis (ring-enhancement) was visible on pretreatment MRI scans in 56% of all lesions and lesions with necrosis
were larger than non-necrotic lesions (6.7 cm3 vs. 3.2 cm3, p = 0.01). Patients with tumor necrosis had a median
survival of 5.4 months, patients without tumor necrosis 7.2 months. Local control rate in the irradiated volume was
70%, median survival without local failure 17.8 months. Control in the brain outside the irradiated volume was 60%,
median survival without distant failure 14.0 months. Significant prognostic factors for overall survival were KPS
(p = 0.001), presence of tumor necrosis on pretreatment MRI (p = 0.001) with RPA-class and WBI reaching marginal
significance (each p = 0.05). Prognostic impact of tumor necrosis remained significant if only smaller tumors with a
volume below 3.5 cm3 (p = 0.03). Side effects were rare, only one patient suffered from serious acute side effects.
Conclusions: Results of this retrospective study support that stereotactic radiotherapy is an effective
treatment option for patients with metastatic brain lesions. The prognostic impact of visible tumor necrosis
(ring-enhancement) on pretreatment MRI scans should be further investigated.
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In the last decades, stereotactic radiosurgery (SRS) has
become a standard treatment procedure for the manage-
ment of certain intracranial lesions, such as brain metas-
tases, and malignant as well as benign brain tumors
[1-12]. Originally developed by Lars Leksell in 1951 as a
substitute for direct surgical intervention, radiosurgery is
a technique that involves single treatment radiotherapy
precisely focused at intracranial targets. The precision of
stereotactic positioning combined with the steep dose
gradients allows sparing normal tissue while reliably
destroying tissue within the target volume. To apply
stereotactic radiotherapy, either a dedicated system (e.g.
Gamma Knife or CyberKnife) or a modified linear acceler-
ator [13] is used. The procedure is more time-consuming
as compared to a standard radiotherapy fraction [14];
however, treatment is convenient for patients, and many
of them prefer the use of stereotactic radiotherapy instead
of surgery because of lower morbidity and side effects but
similar rates of tumor control [15-22].
A recent meta-analysis has evaluated the outcome
after SRS in a variety of neurooncological indications in-
cluding vestibular schwannoma (37 studies with a total
of 3677 patients), meningioma (15 studies with a total of
2734 patients), metastatic disease (27 studies with a total
of 2679 patients), and glioblastoma (11 studies). This
analysis found an overall survival in patients with meta-
static brain lesions of 5-14 months from time of SRS
and a 1-year overall survival rate ranging from 15-55%
with a local control rate of 59% to 97% [23].
In a subset of metastatic lesions, spontaneous necrosis is
visible on magnetic resonance imaging (MRI) [4]. The
presence of visible necrotic areas seems to be a poor prog-
nostic factor in a variety of cancer sites and brain tumors,
especially in malignant gliomas [6]. However, little is
known about the impact of necrosis in metastases which
are treated with radiosurgery. This study investigates a
possible association between tumor necrosis and survival
or tumor control after stereotactic radiosurgery. Further-
more, this study was designed to review the effectiveness
and to determine prognostic factors for survival and local
control as well as the rate of side effects of stereotactic
radiotherapy in patients with brain metastases treated over
a period of more than ten years at the Luebeck University.
Methods
The retrospective study was conducted according to the
principles of the Declaration of Helsinki and to good
clinical guidelines. The study has been notified by the
Ethics Committee, University of Luebeck.
Patient population
From 1998 through 2008, 273 patients received radiosur-
gery or fractionated stereotactic radiotherapy in theDepartment of Radiotherapy at the University of
Luebeck. 103 patients had benign brain tumors (mainly
vestibular schwannoma) and 21 patients were treated be-
cause of malignant primary brain tumors (mainly recur-
rent glioblastoma) or lesions of the base of the skull.
The remaining 149 patients were treated for brain me-
tastases and are the basis of this analysis. Table 1 shows
the distribution of primary tumors. A detailed descrip-
tion of the patient’s characteristics is listed in Table 2.
Treatment
All patients were treated with a linear accelerator (Clinac
2100 C, Varian Inc) with 6 MeV photons and a micro-
MLC. As planning software, BrainScan (BrainLAB
GmbH) was used. In the first years, invasive fixation was
routinely used, but since 2005, all patients were treated
with individually customized mask systems.
136 patients (91%) were treated with a single fraction
with doses between 15 and 27 Gy, the median dose was
22 Gy, prescribed to the surrounding isodose (mostly
the 70%-isodose). Patients without whole brain irradi-
ation (WBI) received doses of 20 to 27 Gy, whereas in
patients with prior or planned WBI, the dose of the
radiosurgical fraction was reduced to 15 to 18 Gy. 13 pa-
tients were treated with hypofractioned radiotherapy
regimens with three to six fractions and single doses of 8
to 12 Gy per fraction.
Tumor necrosis
To determine tumor necrosis, T1-weightend contrast-
enhanced MR-images were required analyzing existence of
visible enhancement. Necrosis was defined as non-
perfused areas at central location of the tumor and a ring
enhancement. A volume calculation was not performed.
MR examinations were performed by different radiolo-
gists (not exclusively neuroradiologists) in different
institutions and were not standardized. Therefore, this
analysis was not blinded and the classification of necro-
sis was done on the basis of written records.
Statistical analysis
Patients were routinely followed in the department, nor-
mally in intervals of 6 and 12 months except patients in
poor general condition. The median follow-up interval
was 12.9 months (range 0.16 - 124 months). Survival
data were determined also by the regional cancer regis-
try (Schleswig-Holstein Cancer Registry); however, 22
patients were lost to follow-up. Furthermore, local and
distant control of 41 patients could not be determined.
All patients were analyzed regarding survival, local,
distant failure and prognostic factors, side effects and
changes in neurologic symptoms after radiotherapy. The
survival time was calculated from the first day of radio-
therapy to the day of the patient’s death or the detection
Table 1 Distribution of primary tumors
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Others (seminoma, prostate-cancer,
follicular thyroid cancer, AML)
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Median dose 22.2 Gy
Median tumor size 4.7 cm3
Range 0.01-33 cm3
Treated with WBI 78 (52)












basal ganglia 5 (3)
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local failure (recurrence in the irradiated volume) as well
as time to any brain failure elsewhere were determined.
The progression of metastases had to be detected by
cerebral computertomography (CCT) or MRI. Different
prognostic factors and their influence on the clinical
endpoint were analyzed, namely age, the localization of
the lesion in the brain, the number of brain metastases,
the Karnofsky performance status (KPS), the recursive
partitioning analysis (RPA) class, tumor necrosis, which
was detected by MRI or CCT, the total dose in Gy, gen-
der, improvement of symptoms, the status of the pri-
mary (active, if the primary tumor is uncontrolled or
other extracranial metastases were detected), tumor size,
the number of extracranial organs with metastatic in-
volvement, additional WBI, the histology of the primary
lesion and the treatment of the primary tumor (chemo-
therapy, surgery or radiotherapy). Also, side effects and
symptomatic changes after radiotherapy were analyzed.
In addition, it was distinguished between improvement,
persistence or deterioration of symptoms.
Survival was estimated with the Kaplan-Meier method
and log rank tests were used to evaluate the effects of
patient characteristics and treatment factors on the clin-
ical endpoints. Univariate and multiple cox proportional
hazards analysis were used. A p-value of < 0.05 was set
as significant. The statistical analysis was performed
using SPSS statistics 16.0 software.other localization 7 (5)
Abbreviations:
KPS Karnofsky performance status, RPA Recursive partitioning analysis, WBI,
Whole brain irradiation.Results
Survival, local control and brain control
At the end of the follow-up (October 1st, 2009), 117
patients had died, 10 patients were still alive and 22
patients were lost to follow-up. The median survival was
7.0 months (range 0.16-88.6 months). After six months,
53% of the patients were still alive. The 1-year and
5-year survival rates were 33% and 0.4%, respectively.
Figure 1 shows the overall survival.The local control rate in the irradiated volume was
61% after one year. The median survival without local
failure was 17.8 months. The control rate in the brain
(remote brain control: outside the target volume in the
brain, that was treated with stereotactic radiosurgery)
Figure 1 Overall survival: overall survival of 149 patients using
the Kaplan-Meier method.
Table 3 Characteristics of patients with or without tumor
necrosis
Parameter N (%) patients without
tumor necrosis
N (%) patients with
tumor necrosis
Age, years




45 (70) 58 (71)
Active 19 (30) 24 (29)
Controlled
KPS median 80% 80%
≥ 90 42 (65) 44 (53)
< 90 22 (35) 38 (46)
Number of
lesions
1 43 (67) 58 (70)
2-3 20 (33) 22 (27)
4-6 0 2 (3)
RPA class
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failure of 14.0 months.I 6 (9) 11 (13)
II 49 (77) 65 (79)







Treated with WBI 48 (58) 29 (45)
Therapy of
primary lesion
Chemotherapy 65 (79) 49 (76)
Radiotherapy 34 (41) 24 (38)
Operation 52 (63) 42 (65)
Abbreviations:
KPS Karnofsky performance status, RPA Recursive partitioning analysis, SRS
stereotactic radiosurgery.Tumor necrosis
In 82 patients (56%), central necrosis was detectable on
pretreatment MRI scans. The distribution of patient-
and tumor-related parameters and prognostic factors
was not different in patients with versus without visible
necrosis (Table 3) except the size of the metastatic lesion
which was higher in tumors with central necrosis
(6.7 cm3 vs. 3.2 cm3, p = 0.01). Patients with tumor ne-
crosis had a median survival of 5.4 months whereas pa-
tients without tumor necrosis had a median survival of
7.2 months. Tumor necrosis (p = 0.001) was a significant
prognostic factors for overall survival in the multivariate
analysis. This relation still applied if only smaller tumors
with a volume below 3.5 cm3 were analyzed (p = 0.03).
Tumor necrosis had no significant effect on local control
(p = 0.3). In a multivariate analysis of all the tumor en-
tities, tumor necrosis is still a significant prognostic fac-
tor (p = 0.01) of survival for patients with lung cancer.
This prognostic impact could not be detected for the
remaining tumor entities.Side effects
No side effects were noted in 88% of the patients. 11%
of the patients had discrete side effects like headache, fa-
tigue or a short-term deterioration of symptoms. In one
case, a hemiataxia (NCI-CTC grade 3) appeared as a ser-
ious side effect after radiotherapy. A symptomatic im-
provement was achieved in 37% of the cases, 48% of the
patients had persistent symptoms and a symptomatic de-
terioration was present in 15% of the cases.Prognostic factors
Following factors were included in the multivariate ana-
lysis: age, KPS, RPA-class, tumor necrosis, additional
WBI, the total dose in Gy, the number of brain metasta-
sis and the localization of the lesion in the brain. The
Karnofsky performance status (p = 0.001) and the pres-
ence of tumor necrosis on pretreatment MRI (p = 0.001)
were the most important prognostic factors in the
multivariate analysis with the RPA-class and WBI as
additional prognostic factors of marginal significance
(p = 0.05). Table 4 shows the results of the univariate
and multivariate analysis.
The most important predictor for local control in a
multivariate analysis was symptomatic improvement
after treatment (p = 0.001). Prognostic factors for brain
Table 4 Univariate and multivariate analysis of survival:





RPA class 0.001 0.05
WBI 0.04 0.05
Tumor necrosis 0.05 0.001
Localization of lesion 0.007 0.002
Number of brain metastasis 0.02 0.09
Dose 0.002 0.64
Gender 0.46
Improvement of symptoms 0.45
Status of primary lesion (active/ controlled) 0.14
Tumor size 0.47





KPS Karnofsky performance status, RPA Recursive partitioning analysis, WBI
Whole brain irradiation.
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metastases in the brain (p = 0.05), the RPA class (p = 0.05)
and the number of extracranial metastases (p = 0.05).
Discussion
Surgery has been the treatment option of first choice in
patients with a single brain metastasis, but radiosurgery
has become an equieffective alternative and standard of
care for patients with one to three brain metastases
[8,24]. Although there are no randomized comparisons
to neurosurgical resection, SRS is considered as equally
effective [1,18]. The role of whole brain radiotherapy in
addition to surgery or SRS remains controversial on the
basis of a recent EORTC-study [7,25]. The study, how-
ever, suggests that SRS yields at least comparable or
even better local control rates than resection, especially
if used as single modality without whole brain radiother-
apy [7]. Nevertheless, local failures in the treated site
occur in about one third of patients. In the EORTC-
study, local failure rates after three years were 59% after
surgery and 31% after radiosurgery, both without WBI.
WBI significantly reduced the failure rates to 27% after
resection and 19% after SRS. WBI also significantly re-
duced failure rate outside the treated volume in the
brain and thereby improved brain control, but had no
impact on overall survival suggesting that either patients
undergoing contemporary diagnostic imaging proce-
dures can effectively be salvaged in case of brain failureor that brain control has a minor impact on survival due
to extracranial progression.
The outcome of patients in this series is comparable
to data in the literature although they are in general
slightly below to recent series. A local control rate of
61% and a brain control rate of 57% are within the range
of figures that have been reported in reviews [23]. The
overall survival is also within the range of reported re-
sults but worse compared to the majority of very recent
study [7,15,26]. A likely explanation might be the fact
that most of the patients in our series (71%) had an ac-
tive extracranial disease at the time of radiosurgical
treatment, reflecting a possible negative selection bias.
Many prospective studies showed that extracerebral con-
trol is a significant impact factor of survival [27,28].
Studies, that reported slightly worse results in survival,
showed a higher number of patients with an active ex-
tracranial disease [29].
Major prognostic factors in patients with brain metas-
tases are the performance status and the activity of ex-
tracranial disease with a number of scoring systems
[21,22,30]. There are limited data in the literature about
the impact of neuroradiological appearance such as MRI
morphologic findings and enhancement patterns of the
metastatic lesions on outcome. In this analysis, necrosis
was defined as non-perfused areas in the tumor on
contrast-enhanced MR images. Recent findings in Ewing
Tumors support this hypothesis [4]. The authors ana-
lyzed the impact of tumor perfusion in MR imaging
studies utilizing contrast-enhanced MR images. Necrotic
areas were defined as non-perfused regions in the tumor.
In Ewing’s sarcomas, the presence of non-perfused
(presumably necrotic) areas on pretreatment contrast-
enhanced MR images is associated with increased risk of
metastases and has prognostic impact in this entity.
Nevertheless, it is currently not clear how far macro-
scopic visualized solid or ring enhancement and micro-
scopic patterns correlate and whether or not they have
the same prognostic impact.
In our study, tumor necrosis was a significant prog-
nostic factor of survival. Our study has some limitations
because analysis as done retrospectively and the MR ex-
aminations were therefore not standardized. Thus, the
results should be interpreted with caution, but might
serve for hypothesis-generating. Patients with tumor
visible necrosis had a median survival of 5.4 months
whereas patients without tumor necrosis had a median
survival of 7.2 months. A likely explanation might be the
effect of hypoxia on radiosensitivity. This hypothesis is
supported by findings in other cancer sites. In patients
with head and neck tumors undergoing definitive radio-
or radiochemotherapy, polarographic measurement of
intratumoral pO2 is a strong predictor for local control
and survival [31]. Moreover, visible necrosis or areas of
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pact [5,32]. In another investigation, the amount of hyp-
oxic volume was the strongest predictor for response to
radiotherapy and survival, suggesting that hypoxia im-
pacts on outcome by reducing radiosensitivity [33,34].
These data suggest that visible necrosis within tumors
on pretreatment images might be a surrogate marker for
relevant radiobiological hypoxia.
Necrosis is the characteristic neuroradiological feature
in glioblastoma. A variety of studies has demonstrated a
significant impact of necrosis on either progression-free
survival or overall survival [6]. However, some investiga-
tions have not found an impact of visible necrosis on
outcome studies, but this may, at least partly, be
explained by the fact that patients with glioblastoma are
treated differently with regard to the extent of surgery.
Nevertheless, the situation might be more complex be-
cause the prognostic effect of tumor necrosis (as defined
here) was - in this analysis - significant only for overall
survival and not for local control. The lack of an associ-
ation between necrosis and local control might be
explained by statistical reasons because data on local
control were less complete than on survival and an effect
on local control might have been missed. On the other
hand, the significant effect on survival suggests that the
presence of necrosis, besides a possible impact on radio-
sensitivity, may be an indicator for a more aggressive
phenotype. In Ewing tumors treated with radiotherapy,
the presence of necrosis on pretreatment MR images
was a strong prognostic factor for local control and sur-
vival and tumors with necrosis had a significant higher
incidence of primary metastases at diagnosis suggesting
that the presence of necrosis is associated with a more
aggressive behaviour of the disease [4]. However, there
was an equal distribution of prognostic factors between
patients with or without necrosis in their metastatic
lesions in our investigation and this finding does not
support the hypothesis that the presence of necrosis is
associated with a more aggressive disease. There is cur-
rently growing interest in hypoxia imaging with the ob-
jective to more precisely deliver radiotherapy to areas
with possible radiation resistance and to improve out-
come after radiotherapy [35]. If a possible association
between visible necrosis and low radiosensitivity could
be supported in future investigations, this might add
useful information in addition to other imaging modal-
ities for radiotherapy planning.
Conclusions
In this analysis, the outcome after stereotactic radiosur-
gery for brain metastases was comparable to data in the
literature with a median overall survival of 7.0 months.
The presence of tumor necrosis on pretreatment
contrast-enhanced MR or CCT images was found to bea prognostic factor for survival irrespective of tumor
volume and its impact should be further investigated.
Abbreviations
CCT: Cerebral computed tomography; CPU: Cancer of unknown primary;
KPS: Karnofsky performance status; MRI: Magnetic resonance imaging;
NCI-CTC: National cancer institute common toxicity criteria; RPA: Recursive
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irradiation.
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